Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

40.99
-0.3148-0.76%
Post-market: 40.990.00000.00%16:10 EDT
Volume:44.88K
Turnover:1.84M
Market Cap:204.13M
PE:- -
High:41.42
Open:41.36
Low:40.84
Close:41.30
52wk High:47.00
52wk Low:29.28
Shares:4.98M
Float Shares:4.98M
Volume Ratio:1.33
T/O Rate:0.90%
Dividend:0.02
Dividend Rate:0.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

Roche's New Breast-Cancer Drug Supports Midterm Growth Outlook

Dow Jones
·
Sep 29

Roche Shows New Research-and-Development Approach is Bearing Fruit

Dow Jones
·
Sep 29

Roche Dashes Hopes of Guidance Upgrade

Dow Jones
·
Sep 29

Roche Needs Next Drug Launches to Go Smoothly

Dow Jones
·
Sep 29

Roche Signals it is Too Soon to Know if AI Improves Trial Success Rates

Dow Jones
·
Sep 29

Roche Seems Increasingly Confident in Obesity Portfolio

Dow Jones
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29